Deanol acetamidobenzoate treatment in choreiform movement disorders.
Deanol acetamidobenzoate was administered in double-blind, crossover fashion with placebo to five patients with tardive dyskinesia, three patients with Huntington's chorea, and one patient with posthemiplegic chorea. No significant effect on dyskinesia was observed. Preliminary administration of physostigmine salicylate to patients with tardive dyskinesia had a variable effect, while benztropine mesylate produced no change. Since the status of deanol as an effective precursor of acetylcholine is uncertain, further trials with putative cholinergic agents remain warranted in choreiform syndromes.
D001590:Benztropine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003642:Deanol / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D004983:Ethanolamines / Q000627:therapeutic use*; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010830:Physostigmine / Q000627:therapeutic use
D004983:Ethanolamines; D001590:Benztropine; D003642:Deanol; D010830:Physostigmine